Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05165433
Title Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd
Indications

carcinoma

adenocarcinoma

Therapies

NG-350A + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.